We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

XRO:ASXXero Limited Analysis

Data as of 2026-03-14 - not real-time

A$80.53

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Xero (XRO) is trading at AUD 80.53, just above its 20‑day SMA of 80.13 but well below the 50‑day (90.23) and 200‑day (140.37) averages, indicating a short‑term bounce within a longer‑term downtrend. The RSI sits at 45, suggesting neutral momentum, while the MACD histogram is positive (0.92) despite the MACD line being below the signal, hinting at a potential bullish reversal. Support at 71.45 and resistance near 89.47 frame the current price, and the stock has recently posted a 12% recovery, which aligns with the optimistic tone in recent Motley Fool commentary. However, volatility remains extremely high at 79% over the past 30 days and volume is decreasing, underscoring a fragile price environment. On the fundamentals side, revenue is growing at 20% YoY with an impressive 89% gross margin and solid operating cash flow, but the valuation is stretched: a trailing P/E of 54 versus an industry average of 34 and a forward P/E of 63. The DCF‑derived fair value of AUD 124.48 implies an upside of roughly 90%, far exceeding current market pricing. While the company’s balance sheet is strong, with cash exceeding debt by a factor of three, the lack of dividend and a modest ROE of 8% limit income‑oriented appeal. The beta of 0.69 points to lower systematic risk, but the tech‑software sector carries inherent high growth risk. In summary, XRO presents a compelling undervalued narrative driven by strong margins and growth, yet the high volatility and bearish medium‑term trend warrant cautious positioning.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just above 20‑day SMA and near support
  • Positive MACD histogram suggesting early reversal
  • High short‑term volatility and decreasing volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth of 20% with 89% gross margin
  • DCF fair value indicating ~90% upside
  • Improving sentiment after recent 12% price recovery

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong cash position relative to debt
  • Sustained high operating margins and expanding product suite
  • Undervalued relative to DCF and growth prospects despite high P/E

Key Metrics & Analysis

Financial Health

Revenue Growth19.90%
Profit Margin11.63%
P/E Ratio54.0
ROE8.29%
ROA4.29%
Debt/Equity29.52
P/B Ratio3.4
Op. Cash FlowA$964.5M
Free Cash FlowA$590.7M
Industry P/E33.7

Technical Analysis

TrendBearish
RSI45.4
SupportA$71.45
ResistanceA$89.47
MA 20A$80.13
MA 50A$90.23
MA 200A$140.37
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueA$124.48
Target PriceA$152.85
Upside/Downside89.80%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.69
Volatility79.05%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.